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Abstract
Background: Despite an augmented research effort and scale-up of highly active antiretroviral therapy, a high
prevalence of HIV-1-associated neurocognitive disorders (HAND) persists in the HIV-infected population. Nearly 50 %
of all HIV-1-infected individuals suffer from a neurocognitive disorder due to neural and synaptodendritic damage.
Challenges in HAND research, including limited availability of brain tissue from HIV patients, variation in HAND
study protocols, and virus genotyping inconsistency and errors, however, have resulted in studies with insufficient
power to delineate molecular mechanisms underlying HAND pathogenesis. There exists, therefore, a great need for
a reliable and centralized resource specific to HAND research, particularly for epidemiological study and surveillance
in resource-limited countries where severe forms of HAND persist.
Description: To address the aforementioned imperative need, here we present the HAND Database, a resource
containing well-curated and up-to-date HAND virus information and associated clinical and epidemiological data.
This database provides information on 5,783 non-redundant HIV-1 sequences from global HAND research published
to date, representing a total of 163 unique individuals that have been assessed for HAND. A user-friendly interface
allows for flexible searching, filtering, browsing, and downloading of data. The most comprehensive database of its
kind, the HAND Database not only bolsters current HAND research by increasing sampling power and reducing
study biases caused by protocol variation and genotyping inconsistency, it allows for comparison between HAND
studies across different dimensions. Development of the HAND Database has also revealed significant knowledge
gaps in HIV-driven neuropathology. These gaps include inadequate sequencing of viral genes beyond env, lack of
HAND viral data from HIV epidemiologically important regions including Asian and Sub-Saharan African countries,
and biased sampling toward the male gender, all factors that impede efforts toward providing an improved quality
of life to HIV-infected individuals, and toward elimination of viruses in the brain.
Conclusion: Our aim with the HAND database is to provide researchers in both the HIV and neuroscience fields a
comprehensive and rigorous data source toward better understanding virus compartmentalization and to help in
design of improved strategies against HAND viruses. We also expect this resource, which will be updated on a
regular basis, to be useful as a reliable reference for further HAND epidemiology studies. The HAND Database is
freely available and accessible online at http://www.handdatabase.org.
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Background
Human immunodeficiency virus (HIV)-associated neu-
rocognitive disorder (HAND) occurs due to damage to
neurons and synapses by viral protein products, and due
to a chemokine/cytokine imbalance in the brain, a pro-
inflammatory response to HIV infection of macrophages
and microglia [1–3]. HIV entry into the brain is an early
event following infection [4], and presence of the blood
brain barrier greatly limits entry of antiretroviral therapy
into the brain. Our ability to control viral levels within
and viral damage to the HIV-infected brain, therefore,
remains highly limited. While the introduction of highly
active antiretroviral therapy (HAART) brought about a
decrease in the incidence of the most severe forms of
HAND, i.e., HIV-associated dementia, the prevalence of
milder forms has continued to increase [5–7]. In the re-
cent HIV Anti-Retroviral Therapy Effects Research
Study, nearly 50 % of all HIV-1 individuals exhibited
some form of HAND, including deficits in motor func-
tion, verbal fluency, learning, memory, and attention [8].
HAND individuals experience difficulty performing day-
to-day tasks, are less likely to adhere to medical
treatments and other HIV-1 prevention practices, and
ultimately suffer from around a threefold increased risk
of death as compared to a mentally-healthy HIV-1 indi-
vidual [9]. In addition, in resource-limited countries, the
most severe forms of HAND continue to devastate the
mental health of HIV individuals [9].
Delineating the underpinning molecular mechanisms
of HAND development is critical to providing HIV-
infected individuals an elevated quality of life, as well as
toward clearance of the virus repertoire in the brain. Re-
search in this area, however, has been largely limited by
availability of samples from both the brain and from
HAND-assessed individuals. In addition, a need to
understand HAND progression across an HIV individ-
ual’s lifespan, coupled with difficulty in obtaining brain
samples, has made cerebrospinal fluid (CSF) sampling a
surrogate endpoint for assessing HAND development
[10]. Both, small sample size from individual studies and
indirect CSF inference have made it difficult to fully as-
sess the complex interaction between viruses and the
brain in the HAND setting. Additionally, variations in
study methodologies and result interpretations have fur-
ther confounded HAND studies, leading to conflicting
findings in the field. To address these issues, there there-
fore exists a great need for a reliable HIV sequence re-
source, of adequate sample size, for HAND research.
Toward this effort, we developed a centralized
HAND Database based on all HAND studies pub-
lished to date. This resource database is freely access-
ible at: http://www.handdatabase.org. The HAND
Database serves as the most comprehensive database
in its field, and contains well-curated HAND virus
information, epidemiology sampling data, patient clin-
ical status, and therapy treatment information. All
information was cross-validated using multiple re-
sources, including the literature, GenBank entry, and
author contact. Furthermore, all viral sequences have
undergone stringent quality control examination, in-
cluding genotyping validation, in order to minimize
genotyping errors frequently seen in HIV subtype-
based studies [11].
The only other published HIV database related to
brain tissue, The HIV Brain Sequence Database [12],
contains HIV env sequences from brain tissue, as well as
from other tissues in patients with brain samples. In
contrast, our database contains HAND-specific informa-
tion with regards to virus sequences (genome coverage
beyond env), epidemiology sampling information, clinical
data, and treatment status, all factors important to the
study of HAND pathogenesis. Unprecedented in its
comprehensiveness of curated HAND HIV information,
our HAND Database serves as a centralized gateway to
study the role of HIV in the HAND setting.
Construction and content
Data sources
An extensive literature review was conducted to develop
a comprehensive set of HAND-related research articles,
from which we then extracted sequence data from
HAND-assessed individuals. This literature search re-
sulted in the use of data from 41 published studies. Pub-
lically available HIV-1 sequence data were collected
from the GenBank (last accessed 3/2013) and the LANL
HIV sequence database (last accessed 2/2014) [13, 14].
HIV-1 individual sampling and clinical information was
collected from the relevant literature, the two aforemen-
tioned databases, and through communication with pub-
lication authors.
Sequence and clinical data filtering
All collected sequence data were validated through a
series of quality control steps. We first employed the
LANL quality control pipeline to check for potential prob-
lematic viruses with sequencing errors [13]. Amplification
contamination was detected using BLASTn (v. 2.2.26)
[15]. In addition, data regarding epidemiology sampling,
clinical status, and treatment status were cross-referenced
whenever available in more than one of the resources
listed above.
Genotyping analysis
Genotyping of HIV sequence data is frequently incon-
sistent and error-prone [11].
Therefore, all filtered HIV sequences were re-
genotyped. Here we applied the jumping profile Hidden
Markov Model genotyping program (jpHMM), whose
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genotyping accuracy has been established [16–18]. In
brief, following a hypermutation analysis [13], sequences
greater than 300 nucleotides in length and with a hyper-
mutation p-value of 0.05 or greater were subject to
genotyping.
Database schema
The HAND Database was constructed using the rela-
tional database management system MySQL (v.5.6.17).
MySQL was chosen for its ease of use, its high reliabil-
ity, and as it is freely available. HIV-1 sequence and
clinical data were compiled into one flat file, with anno-
tations divided into three major categories: sequence
and sequence descriptor data, HIV-1 patient descriptor
data, and sample descriptor data (Table 1). Sequence
data included the HIV-1 nucleotide sequence, sequence
accession number, sequence genotype information, and
sequence length. Epidemiology data included the geo-
graphical location and year at time of sampling, as well
as tissue sampled. Patient data at time of sampling in-
cluded patient age, risk factor, health status, CD4 count,
viral load, HIV treatment information (treatment sta-
tus, and when applicable, treatment type and duration),
and patient HAND information (HAND status, the
presence or absence of HAND, and when applicable,
HAND type).
Utility
Database access and web query interface
The HAND Database was developed into a publically
available, web accessible resource. The database website
provides a home page with background information on
HAND, as well as a help page to assist with database
navigation (Fig. 1). The database itself allows for easy
Table 1 Overview of database annotations
Category Annotation Example Explanation
Patient Patient: Code SUBJECT_4 The originating publication ID for this patient was “SUBJECT_4”
Patient Patient: HAND
Status
HIVE + ADC This patient had two forms of HAND: HIVE and ADC
Patient Patient: Sex M This patient was male
Patient Patient: Risk Factor IV Drug User This patient may have contracted the HIV virus through IV drug use




Information on this patient’s viral load at time of sampling could not be found
Patient Patient: CD4 Count
At Sampling
5 cells/ul This patient had a CD4 count of 5 cells/ul at time of sampling
Patient Patient: HIV Therapy
Status
AZT This patient had received AZT therapy prior to sampling
Patient Patient: HIV Therapy
Months
20 This patient had received HIV therapy for 20 months prior to sampling
Patient Patient: Age At
Sampling
29 This patient was 29 years of age at time of sampling
Patient Patient: Health At
Sampling
AIDS This patient had AIDS at time of sampling





This sample was obtained in an unknown city in the country of Japan
Sampling Sampling: Tissue Spleen This sample was obtained from spleen tissue
Sequence Sequence: Polyprotein
(Protein)
Tat (gp160) This sequence segment covers the Tat and Gp160 HIV regions
Sequence Sequence: Genotyping
Information1
B (B)* This sequence was listed by the originating data source as a B subtype sequence. jpHMM
genotyping confirmed subtype as B. Recombination testing detected recombination events in
this sequence (indicated by the asterisk).
Sequence Sequence: Accession
Number
U82096 The sequence accession number for this sequence is U82096
Sequence Sequence: PMID 9718130 The sequence PMID for this sequence is 9718130
Sequence Sequence: Length
in Nucleotides
150 The sequence length for this sequence segment is 150 nucleotides
Sequence HIV Sequence cccaaat… The nucleotide sequence for this sequence is “cccaaat…”
1The sequence genotyping annotation provides genotyping and recombination information in the following format: Subtype as reported in the original source
material (Subtype as reported by jpHMM genotyping) and recombination information. Additional symbols used in this annotation include: “#” = not tested due to
insufficient length of sequence, “*” = p < 0.05 for recombination test, “(No)” = p > 0.05 for recombination test
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querying and downloading of user-defined data subsets.
Researchers can perform a simple search using a key-
word, or employ multiple column filters for a custom-
made data subset. Selected entries can subsequently be
downloaded into a variety of formats at the user’s discre-
tion. Additional features include sorting by annotation
of interest, as well as an option for viewing the complete
record for any given entry.
Database content
The HAND Database currently contains 5,783 HIV-1
sequences, representing a total of 163 unique individ-
uals assessed for HAND status. For the 87 individuals
with age information available, ages ranged from 19 to
63 years, with the largest proportion of individuals be-
tween 30 and 49 years of age (69 %) (Fig. 2). Gender in-
formation was available for 64 individuals, the majority
of whom were males (77 %). HAND status, the absence
or presence of HAND, was obtained for almost all data-
base individuals (96 %), and indicated a close split be-
tween non-HAND (44 %) and HAND (52 %) patients.
The top three reported HAND types in HAND-positive
individuals were HIV-1-associated dementia (HAD,
54 %), HIV-1 encephalopathy (HIVE, 35 %), and AIDS
dementia complex (ADC, 8 %) (Fig. 3). HIV treatment
status information, whether or not an individual had
received HIV treatment prior to sampling, was available
for 67 % of individuals, and the majority of individuals
with treatment information had received some form of
treatment (49 %). Nearly half of all treated individuals
had received HAART (46 %) prior to sampling, while
Fig. 1 The HAND Database Search Interface. The HAND Database provides flexible searching, filtering, and browsing capabilities. Sequence
entries and annotations of interest can be exported into a variety of file formats for further use. In addition, a website navigation bar allows easy
access to help, contact, and background information pages
Fig. 2 Distribution of HAND Database Entries By Age. Age
distribution across database individuals showed 69 % of individuals
for whom this information was available were between the ages of
30 to 49 years
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the rest had received one or more forms of HIV mono-
therapy (54 %) (Fig. 4).
Geographical region sampling information was avail-
able for 156 patients, with the top three sampling re-
gions being North America (60 %), Europe (25 %), and
Asia (6.4 %) (Fig. 5). Samples were derived from 20 dif-
ferent tissue types, with the top three sampling tissues
being brain (47 %), lymph node (14 %), and CSF (7 %).
Five HIV-1 genes were represented in our database, gag,
pol, env, tat, and nef, with the majority of sequence cover-
age in the env gene (Fig. 6). This result was expected due
the known role of env in macrophage tropism, viral repli-
cation, and activation of pro-inflammatory responses to-
ward neuronal injury [19–21]. Of all archived sequences,
79 % of sequences that underwent genotyping validation
were of the pure B subtype, and all non-recombinant se-
quences were confirmed as having been correctly reported
Fig. 3 Distribution of HAND Database Entries By HAND Status And
HAND Type. The top chart shows HAND status distribution across all
database individuals, and the bottom chart shows HAND type
distribution across database individuals for whom this information
was available. The majority of individuals with HAND had HIV-
associated dementia (HAD), followed by HIV-encephalitis (HIVE), AIDS
dementia complex (ADC), and minor cognitive-motor disorder
(MCMD). HAND type designations were obtained from the literature,
and for some individuals, more than one HAND type had
been assigned
Fig. 4 Distribution of HAND Database Entries By HIV Therapy Status
And HIV Therapy Type. The top chart shows HIV therapy status
distribution across all database individuals, and the bottom chart
shows HIV therapy type distribution across database individuals for
whom this information was available. Nearly half of all treated
individuals had received HAART. Therapy type designations were as
we found to be reported in the literature, and for some individuals,
more than one HIV therapy type had been assigned
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in the literature. Sixteen sequences were found to have
undergone recombination events not reported in either
the source literature or databases.
Discussion
Despite increased HAND research and treatment efforts,
the persistent prevalence of HAND continues to pose a
great challenge to the HIV research and patient commu-
nities. Investigation in this area is limited by small sam-
ple sizes, primarily due to difficulty in obtaining tissue
samples, and by variation in study protocols and result
interpretation. Furthermore, errors and inconsistency in
HIV genotyping compound the complexity in delineating
viral mechanisms toward neuropathology. The HAND
Database described here serves to narrow these research
gaps and addresses the need for a reliable and central-
ized HAND data source for advanced research purposes.
The HAND database contains up-to-date and well-
curated HAND virus and patient information. All
sequence data have been subject to stringent quality
control examination and re-genotyping, thereby laying a
solid foundation toward elucidation of viral mechanisms
driving neuropathology under various epidemiology
settings.
Fig. 5 Distribution of HAND Database Entries By Sampling
Geographical Region. Sampling geographical region distribution
across database individuals showed the majority of database
sequence entries for whom this information was available were
derived from North American samples
Fig. 6 HAND Database HIV-1 Genome Coverage And Sequencing Depth. The top panel displays HAND Database sequencing depth across the
HXB2 reference sequence, and the bottom panel displays HIV-1 gene location across the HXB2 reference sequence. The env gene was the HIV
genomic region with the greatest sequencing depth. HXB2 accession number: K03455
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In creating this resource we noted a number of sequen-
cing and sampling biases that currently limit research in
the area, and have developed a set of potential research di-
rections that may greatly benefit the HAND research
community. First, although prior studies have indicated
the role of multiple HIV proteins, including Nef, Vpr, and
Tat [22–29], toward HAND development, the majority of
research in the area has focused on the gp120 envelope
glycoprotein. This sequencing bias is largely due to inter-
est in Env for its role in conferring viral tropism for
microglia and macrophage cells [30–33], its role in non-
neuronal cell replication [34], and for its potential as an
HIV therapeutic target [35]. A shortage of sequence data
beyond the env gene, however, limits our ability to per-
form data-driven HAND research on the complete viral
genome, and therefore an increase in sequencing efforts in
other areas of the genome would provide insight into the
role of regulatory and accessory proteins toward HAND
pathogenesis. Second, there is a distinct lack of sequence
data from HIV epidemiologically important regions in-
cluding many Asian and Sub-Saharan African countries
(Fig. 5). Limited access to HAART contributes to an in-
creased vulnerability of HIV individuals in these geo-
graphical regions to the most severe forms of HAND.
Recent studies indicate HIV-associated dementia (HAD)
affects over 25 % of HIV individuals in several Sub-
Saharan African countries [36–38]. In addition, research
on treatment-naïve HIV-1-individuals in Thailand has
greatly contributed to our understanding of HAND patho-
genesis [39]. Finally, we noted a bias toward sequencing of
male individuals. Research beyond the HIV field has impli-
cated gender as playing a role in determining those gen-
etic processes leading to neurocognitive deficiencies [40,
41]. A lack of information on HAND females, however,
currently proves an obstacle in determining potential gen-
der differences in HAND pathogenesis.
Conclusions
Developing a better understanding of mechanisms
underlying the development of neurocognitive disorders
is crucial toward providing the HIV patient community
with a higher quality of life, and toward prevention of
enhanced transmission. Through consolidation and val-
idation of data from multiple data sources, here we have
developed the HAND Database, a single, intuitive plat-
form from which researchers can launch their high-
throughput HAND sequencing projects. The HAND
database contains up-to-date and curated HAND HIV
virus and HIV-infected individual information, providing
a solid foundation toward the elucidation of viral mecha-
nisms driving this neuropathology. In particular, we an-
ticipate this database will be of great use in increasing
HAND research efforts in resource-limited countries.
We plan to continue expanding the HAND Database
as new HAND viral sequence data become publically
available.
Availability and requirements
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